By Brad Sorensen, CFA
NASDAQ: COSM
READ THE FULL COSM RESEARCH REPORT
The latest announcement from Cosmos Health Inc. (NASDAQ: COSM) regarding the planned U.S. launch of Liv18 represents a strategically coherent step in the company’s broader effort to reposition itself around higher-margin, science-backed nutraceutical products.
Highlighting this investment thesis is the market opportunity Liv18 is targeting. Liver disease—specifically metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD—has quietly become one of the most prevalent chronic conditions in developed markets. More than 30% of U.S. adults are estimated to be affected, driven largely by obesity, diabetes, and metabolic syndrome trends. This creates a large and underpenetrated preventive-care market, particularly because pharmaceutical interventions remain limited or are focused on more advanced disease states. Against this backdrop, the U.S. liver health supplement market is already estimated at approximately $4.6 billion, with expected mid-single-digit annual growth through the next decade.
We view Liv18’s positioning as designed to bridge the gap between wellness supplements and clinically validated interventions. The product is built around BergacynFF, a patented botanical blend derived from bergamot and wild artichoke, standardized for specific bioactive compounds including flavonoids and sesquiterpenes. These compounds are associated with anti-inflammatory, antioxidant, and lipid-modulating effects—key pathways implicated in liver fat accumulation and metabolic dysfunction. The emphasis on a “synergistic blend” is important from an investment perspective, as it provides both intellectual property protection and a marketing narrative that differentiates the product from commoditized single-ingredient supplements.
What elevates Liv18 above many nutraceutical peers is the level of clinical validation. The underlying ingredient has been tested in two randomized, double-blind, placebo-controlled trials—the gold standard in clinical research, and still relatively uncommon in the supplement industry. In a 16-week study involving patients with NAFLD and type 2 diabetes, participants demonstrated statistically significant reductions in key liver enzymes (ALT and AST) along with regression in liver fat severity. A second 12-week study in non-diabetic individuals with liver steatosis showed a roughly 9% reduction in liver fat versus placebo, with even stronger results (approximately 15%) in older populations. Notably, the trials also indicated ancillary benefits such as weight loss and improvements in inflammatory markers, suggesting a broader metabolic impact rather than a narrowly targeted liver effect.
From our point of view, this clinical backing is central. The supplement industry is often criticized for weak evidence and limited regulatory oversight, which compresses pricing power and increases competition. By contrast, Cosmos Health is attempting to position Liv18 closer to a “medical-grade” nutraceutical—supported by published human trials at the commercial dose level. If successfully communicated to consumers and healthcare practitioners, this could enable premium pricing, physician channel penetration, and stronger brand loyalty.
Commercially, the go-to-market strategy reflects a hybrid distribution model spanning e-commerce, retail, and practitioner channels. This is important because practitioner endorsement can materially influence supplement adoption in categories tied to chronic conditions, while e-commerce provides scalability and margin efficiency. Additionally, U.S.-based manufacturing in GMP-certified, FDA-registered facilities reduces regulatory risk and supports quality positioning—an increasingly important factor in consumer health products.
Ultimately, the Liv18 launch reflects a broader strategic pivot toward evidence-based nutraceuticals targeting large chronic health markets. For investors, the key question is not whether the science is compelling—it appears to be—but whether Cosmos Health can operationalize that science into sustained revenue growth and improved financial performance.
The success of LIV8 ultimately depends on the market penetration achieved by Cosmos and how the company can grow market acceptance and use of the product. The company has proven it can roll out products successfully and we are confident that the COSM price target will be raised in the not-too-distant future as market penetration of LIV18 begins to be realized.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.